Fannin Partners has been awarded a $300,000 Phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) to advance a first-in-class, non-VEGF–targeted therapeutic for ...
The vascular endothelial growth factor (VEGF) pathway is well established as one of the key regulators of this process. The VEGF/VEGF-receptor axis is composed of multiple ligands and receptors with ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PARK CITY, Utah — In this Healio Video Perspective from ...
Direct anti-VEGF angiogenic agents were a strong risk factor for high-grade hypertension, and multikinase inhibitors for high-grade proteinuria. Vascular endothelial growth factor signaling pathway ...
Please provide your email address to receive an email when new articles are posted on . Bispecifics are a relatively new area in ophthalmology. In 2022, faricimab was the first-ever FDA-approved ...
Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...
– Data support casdozo as a promising novel immuno-oncology agent with clinical activity in liver cancer that may be associated with IL-27 pathway biomarkers – – Data support continued evaluation of ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback